Posted by Michael Wonder on 01 Jul 2021
FDA approves component of treatment regimen for most common childhood cancer
30 June 2021 - Today, the U.S. FDA approved Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) as a component of a chemotherapy regimen to treat acute lymphoblastic leukaemia and lymphoblastic lymphoma in adult and paediatric patients who are allergic to the E. coli derived asparaginase products used most commonly for treatment.
The only other FDA approved drug for such patients with allergic reactions has been in global shortage for years.
